Efficacy, Safety, and Treatment-Delivery Feasibility of Autologous Gene Therapy for Sickle Cell Disease: A Systematic Review With Descriptive Synthesis of Clinical Trials.
Mahboob Younus Shaik, Stephen Divers
✦ AI-curated · Sources linked
In 30 seconds
This systematic review with descriptive synthesis assessed efficacy, safety, and delivery feasibility of autologous gene therapy for sickle cell disease across nine interventional clinical programs and associated follow-up reports. The 25 reports included 148 infused patients treated with lentiviral, shmiR, CRISPR-Cas9, CRISPR-Cas12a, or base-editing approaches. In pivotal cohorts, prospectively defined VF12 was 96.7% (29/30) with exa-cel, while severe VOE resolution was 100% (25/25) with lovo-cel; both products achieved transfusion independence in evaluable patients. The authors describe substantial short- to medium-term benefit, with long-term safety and delivery challenges unresolved.
Key findings
- Prospectively defined VF12 was 96.7% (29/30) in the exa-cel pivotal cohort.
- Severe VOE resolution was 100% (25/25) in the lovo-cel pivotal cohort.
- Both exa-cel and lovo-cel achieved transfusion independence in evaluable patients.
- Treatment delivery varied: 44/46 patients were infused for exa-cel and 35/47 for lovo-cel.
Why it matters
The synthesis indicates that several autologous gene-therapy platforms can substantially reduce severe vaso-occlusive events and improve hemoglobin biology over short to medium follow-up. It also highlights that clinical benefit depends on a multistep delivery pathway, not efficacy alone. Mobilization, collection, manufacturing, conditioning, fertility preservation, cost, and long-term surveillance are relevant to assessing feasibility and access.
What to keep in mind
Evidence is limited by single-arm designs, small samples, evolving protocols, heterogeneous endpoint definitions, and incomplete long-term follow-up; the review did not formally pool efficacy outcomes.